Unicycive Therapeutics Q1 net loss widens on warrant liability

Unicycive Therapeutics

Unicycive Therapeutics

UNCY

0.00


Overview

  • U.S. kidney disease biotech reported Q1 net loss widened mainly due to warrant liability changes

  • R&D expense fell while G&A costs rose in Q1 2026


Result Drivers

  • R&D EXPENSES - Lower research and development costs due to reduced drug development and consulting fees

  • G&A EXPENSES - Higher general and administrative costs from increased consulting, professional services, and labor

  • WARRANT LIABILITY - Net loss increase mainly due to change in fair value of warrant liability


Company press release: ID:nGNXbkHB8j


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$12.82 mln

Q1 Income from Operations

-$8.44 mln

Q1 Operating Expenses

$8.44 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $31.00, about 289.9% above its May 11 closing price of $7.95

  • The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 11 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.